Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lin Gui

Showing results (231-240 of 251) with videos related to

Pageof 26
Sort By:
International Journal of Hematology|November 22, 2013
High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysisLin Gui, Yuan-kai Shi, Xiao-hui He, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|September 19, 2014
Clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphomaBo Jia, Yuankai Shi, Mei Dong, et al.
Hematology (Amsterdam, Netherlands)|April 15, 2016
Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomasBo Jia, Shaoxuan Hu, Jianliang Yang, et al.
Therapeutic Advances in Medical Oncology|September 15, 2025
Combination of immunotherapy-based systemic therapy and radiotherapy achieves durable response and favorable survival in recurrent head and neck cancerJingbo Wang, Gulidanna Shayan, Xin Guo, et al.
Redox Biology|February 28, 2026
NMRK2-YAP-NADK axis preserves redox protection against myocardial ischemia/reperfusion injuryChao Zhang, Jie Wang, Jing Chi, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi|October 17, 2020
[Analysis of Transfusion Therapy Effectiveness in Patients with Myelodysplastic Syndrome]Zhen-Hua Yin, Zhi-Rui Pang, Xian-Chun Fang, et al.
Chinese Medical Journal|September 15, 2015
Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with LymphomasPing Zhou, Peng Liu, Sheng-Yu Zhou, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 30, 2023
A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera<sup>®</sup>) in patients with CD20-positive B-cell non-Hodgkin lymphomaXiaohong Han, Mingzhi Zhang, Huaqing Wang, et al.
BMJ Open|June 3, 2019
Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in ChinaShiyu Jiang, Peng Liu, Sheng Yang, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|November 7, 2015
Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphomaBo Jia, Yuankai Shi, Suyi Kang, et al.
Pageof 26

Showing results (231-240 of 251) with videos related to

Sort By:
Pageof 26
International Journal of Hematology|November 22, 2013
High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysisLin Gui, Yuan-kai Shi, Xiao-hui He, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|September 19, 2014
Clinical features, survival and prognostic factors of primary testicular diffuse large B-cell lymphomaBo Jia, Yuankai Shi, Mei Dong, et al.
Hematology (Amsterdam, Netherlands)|April 15, 2016
Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomasBo Jia, Shaoxuan Hu, Jianliang Yang, et al.
Therapeutic Advances in Medical Oncology|September 15, 2025
Combination of immunotherapy-based systemic therapy and radiotherapy achieves durable response and favorable survival in recurrent head and neck cancerJingbo Wang, Gulidanna Shayan, Xin Guo, et al.
Redox Biology|February 28, 2026
NMRK2-YAP-NADK axis preserves redox protection against myocardial ischemia/reperfusion injuryChao Zhang, Jie Wang, Jing Chi, et al.
Zhongguo Shi Yan Xue Ye Xue Za Zhi|October 17, 2020
[Analysis of Transfusion Therapy Effectiveness in Patients with Myelodysplastic Syndrome]Zhen-Hua Yin, Zhi-Rui Pang, Xian-Chun Fang, et al.
Chinese Medical Journal|September 15, 2015
Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with LymphomasPing Zhou, Peng Liu, Sheng-Yu Zhou, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|January 30, 2023
A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera<sup>®</sup>) in patients with CD20-positive B-cell non-Hodgkin lymphomaXiaohong Han, Mingzhi Zhang, Huaqing Wang, et al.
BMJ Open|June 3, 2019
Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in ChinaShiyu Jiang, Peng Liu, Sheng Yang, et al.
Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu|November 7, 2015
Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphomaBo Jia, Yuankai Shi, Suyi Kang, et al.
Pageof 26